*Only for reading and reference by medical professionals
The recovery rate of urinary control function in early-stage patients is 97%, and the recovery rate of sexual function is over 70%...
"The 5-year survival rate of early-stage patients is nearly 100%, and urinary control function is restored The rate is 97%, and the sexual function recovery rate is over 70% %..." Recently, news came from the 2022 Prostate Cancer Academic Week and Pujiang Prostate Cancer Summit Forum. Conference Chairman and Professor Ye Dingwei of Fudan University Affiliated Tumor Hospital led a team to release the results of treatment in the hospital. Curative effect data on more than 6,000 early-stage prostate cancer patients. Through the original "re-swelling technique" of radical prostate cancer surgery, the urology team of the cancer hospital accurately treats tumors while protecting the male body function as much as possible, improving the patient's quality of life, and making prostate cancer no longer an unspeakable disease.
According to Professor Ye Dingwei, my country is a major country for prostate cancer. The latest statistics from the World Health Organization show that there will be more than 110,000 new cases of prostate cancer in China in 2020. Compared with developed countries in Europe and the United States, prostate cancer patients in my country have a high proportion of late-stage disease, a lower 5-year survival rate, and poorer quality of life. Although early patients have the opportunity for radical surgery, problems such as postoperative urinary incontinence and loss of sexual function are still their biggest "concerns" that they are "afraid" of surgery. With the improvement of living standards, more and more patients not only pursue good treatment effects, but also hope to obtain better quality of life.
With the help of "double surgical robots",
accurately solves the problem of "hidden men's speech"
The prostate surrounds the urethra and is in close contact with the sexual nerve plexus, so prostatectomy surgery can easily damage urinary control and sexual function. Data shows that if during the operation Precise function-preserving surgery cannot be performed. The erectile dysfunction rate after prostate cancer surgery is as high as 95%, and the incidence of short-term urinary incontinence after surgery is as high as 50%. Therefore, prostate cancer often becomes a "masculine secret" for many men, and whether to undergo radical surgery becomes a dilemma. How can
protect function in prostate cancer patients to a greater extent? It tests the surgical skills of many urological surgeons. In order to achieve precise surgery for prostate cancer, Professor Ye Dingwei led a team that benchmarked internationally advanced surgical technology concepts, independently innovated and summarized surgical techniques suitable for the structural characteristics of Chinese people, and developed the "rejuvenation technique" for radical prostate cancer surgery. Through five key surgical steps: structural identification, sexual function protection, urinary control function protection, hemostasis and leakage prevention, and pelvic floor reconstruction, the patient's functional recovery and postoperative safety are ensured while maximizing the radical cure of the tumor. Professor Ye's team used this original "rejuvenation technique" combined with the most advanced robotic surgery system to successfully relieve pain, preserve function, and return to normal life for a large number of early-stage prostate cancer patients. Regarding the issues of positive resection margins and local invasion that are of concern to patients with locally advanced disease, Professor Ye Dingwei’s team used the excellent magnification effect of the robotic surgical imaging system to magnify the small prostate by more than 10 times and perform optimal treatment by identifying subtle invasions. The resection route, combined with various vesicourethral reconstruction and structural protection surgical techniques, allows patients to achieve better outcomes.
"
Professor Ye Dingwei said: "At present, our hospital's second new generation da Vinci surgical robot has been installed for surgery, entering the "dual machine" era. It is also the only hospital in Shanghai that has two 4th generation da Vinci surgical robots. . This initiative to benefit the people has greatly shortened the appointment time for robotic surgery, changed the embarrassing situation of "few machines, many patients, and one machine is hard to find", and provided more patients with excellent tumor control and functional protection brought by precise minimally invasive robots, allowing The male compatriots can truly "retract and relax freely and regain their glory" after the operation. "
"
Fudan Cancer's prostate cancer surgery team has received recognition in the industry for its superb surgical skills, leading surgical volume in the country, and the greatest "three consecutive wins" (good tumor control, low incidence of urinary leakage, and good recovery of sexual function). It is widely recognized that the team will also take the lead in clinical research related to domestic surgical robots. China's independent property rights surgical robots combined with Professor Ye's original "rejuvenation technique" for Chinese people will be deeply integrated and collide to produce higher-quality surgeries.
Metastatic prostate cancer also has the opportunity for surgery,
makes the "Chinese voice" on the international stage for the first time
Metastatic prostate cancer has traditionally been treated with drugs, and most opinions believe that the value of resection of the primary prostate lesion is limited. Can patients with metastatic prostate cancer also achieve good results through surgery? Professor Ye Dingwei's team relied on years of clinical experience to conduct a rigorous randomized controlled clinical study.
Professor Ye Dingwei, the designer and leader of the
study, said: “This study is the first to prove that prostate cancer patients with ≤5 metastatic lesions and no visceral metastasis (oligo-metastasis) can undergo surgical resection of the primary prostate lesion. Or radiotherapy , which increased the three-year overall survival rate of such patients by 18%. The research results were also published by European Urological Oncology, the top international journal in the field of urological tumors, which also marks a new step in the treatment of urological tumors in China. "
"
This study is the first to clarify that surgical resection of primary prostate lesions in patients with metastatic prostate cancer can significantly improve the patient's survival rate. It is the first time to use real data from the Chinese population to establish the value of surgical treatment for patients with oligometastatic prostate cancer. It is expected to change the current clinical treatment strategy for oligometastatic prostate cancer.
A multidisciplinary expert team enables top
new drugs at home and abroad new technologies to cover prostate cancer patients at all stages
The purpose of clinical research is to analyze and clarify the safety and effectiveness of new drugs or new treatment technologies in clinical diagnosis and treatment of tumors, representing A new direction for future diagnosis and treatment, while also providing patients with optimal diagnosis and treatment plans. It is understood that as a leader in the field of clinical research in urology, Professor Ye Dingwei has led more than 70 clinical studies in the field of urological tumors, allowing countless patients with urological tumors to obtain better marketed drugs. Because of his authority, Professor Ye Dingwei is also the editor-in-chief of the well-known CSCO Prostate Cancer Guidelines and CACA Prostate Cancer Guidelines in China, and is also the only author of the St. Gallen Consensus on Prostate Cancer (APCCC) in mainland China, the "palace level" club of the international urological oncology community. Representatives, so that the development of domestic clinical research and the use of new drugs and technologies are always in line with international standards.
"
Professor Ye Dingwei said: "The development of innovative drugs and new technologies for urological tumors started late and has little say in the international arena. Over the years, the urology department team of the Cancer Hospital has been deeply involved in the field of prostate cancer and has taken the lead in developing many innovative drugs and new technologies for prostate cancer. Clinical research on The urological tumor center covers the full course of clinical research in the early, intermediate and late stages. The most accurate diagnosis and treatment plan is formulated by a multidisciplinary expert team of urological tumors, and the most complete evaluation methods and the most advanced treatment methods are applied. Multidisciplinary experts follow up throughout the process. Treatment effects, timely evaluation of disease adjustment plans, and timely treatment of side effects give prostate cancer patients the chance to live longer and better lives.
”
It is reported that the multidisciplinary expert team of urological oncology led by Professor Ye Dingwei has provided tens of thousands of patients with lack of effective drug treatment and average family economic conditions in recent years with the latest and most advanced international and domestic services without leaving Shanghai. Opportunities for therapeutic drugs and diagnostic and treatment technologies are large It greatly reduces the pain and economic burden of patients and benefits the broadest group of urological tumor patients.
This article was first published by: Tumor Hospital of Fudan University.
Author of this article: Zhu Yu.
Editor: Sweet
Copyright statement.
Original article. If you need to reprint, please contact us for authorization.
- End -
* The medical community strives to ensure that the published content is accurate and reliable when approved, but it does not guarantee the timeliness of the published content, as well as the accuracy and completeness of the cited materials (if any). We do not make any commitments or guarantees, nor do we assume any responsibility due to the fact that the content is out of date, the referenced information may be inaccurate or incomplete, etc. Relevant parties are requested to check separately when adopting or using it as a basis for decision-making.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-